These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 20170332

  • 1. Does low-dose seretide reverse chronic obstructive pulmonary disease and are the benefits sustained over time? An open-label Swedish crossover cohort study between 1999 and 2005.
    Rustscheff S, Rydén L.
    J Asthma; 2010 Mar; 47(2):214-6. PubMed ID: 20170332
    [Abstract] [Full Text] [Related]

  • 2. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 3. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 4. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 5. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A, Szalai Z, Pullerits T, Radeczky E.
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [Abstract] [Full Text] [Related]

  • 6. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 7. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 9. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C, Petroianni A, Ricci A, Allegra L.
    Eur Rev Med Pharmacol Sci; 2005 Jun; 9(4):209-15. PubMed ID: 16128040
    [Abstract] [Full Text] [Related]

  • 11. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 14. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 15. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
    Fardon T, Haggart K, Lee DK, Lipworth BJ.
    Respir Med; 2007 Jun 13; 101(6):1218-28. PubMed ID: 17178217
    [Abstract] [Full Text] [Related]

  • 16. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec 13; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 17. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
    Thompson WH, Carvalho P, Souza JP, Charan NB.
    Lung; 2002 Dec 13; 180(4):191-201. PubMed ID: 12391509
    [Abstract] [Full Text] [Related]

  • 18. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 Dec 13; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
    Clin Ther; 2007 Jun 13; 29(6):1203-13. PubMed ID: 17692734
    [Abstract] [Full Text] [Related]

  • 20. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.